0001567619-20-018006.txt : 20201020 0001567619-20-018006.hdr.sgml : 20201020 20201020165718 ACCESSION NUMBER: 0001567619-20-018006 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201020 FILED AS OF DATE: 20201020 DATE AS OF CHANGE: 20201020 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Symons Julian A. CENTRAL INDEX KEY: 0001824727 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39617 FILM NUMBER: 201248783 MAIL ADDRESS: STREET 1: C/O ALIGOS THERAPEUTICS, INC. STREET 2: ONE CORPORATE DRIVE, 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aligos Therapeutics, Inc. CENTRAL INDEX KEY: 0001799448 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (800) 466-6059 MAIL ADDRESS: STREET 1: ONE CORPORATE DR., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc1.xml FORM 4 X0306 4 2020-10-20 0 0001799448 Aligos Therapeutics, Inc. ALGS 0001824727 Symons Julian A. C/O ALIGOS THERAPEUTICS, INC. 1 CORPORATE DRIVE, 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Common Stock 2020-10-20 4 C 0 13671 A 389218 D Common Stock 2020-10-20 4 C 0 3394 A 392612 D Common Stock 2020-10-20 4 C 0 1452 A 394064 D Series A Preferred Stock 2020-10-20 4 C 0 13671 0.00 D Common Stock 13671 0 D Series B-1 Preferred Stock 2020-10-20 4 C 0 3394 0.00 D Common Stock 3394 0 D Series B-2 Preferred Stock 2020-10-20 4 C 0 1452 0.00 D Common Stock 1452 0 D Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. /s/ Lucinda Y. Quan, as attorney-in fact for Julian A. Symons 2020-10-20